STMicroelectronics NV vs TransMedics Group Inc — how do they compare? STMicroelectronics NV trades at $55.04 (market cap $49.21B), while TransMedics Group Inc trades at $87.03 (market cap $3.10B). The key difference: STMicroelectronics NV is far larger — about 15.9× TransMedics Group Inc's market cap, and STMicroelectronics NV pays a 0.65% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| STM | TMDX | |
|---|---|---|
Market Cap | $49.21B | $3.10B |
Sector | Financials | Technology |
52-Week High | $79.91 | $150.42 |
52-Week Low | $21.20 | $61.99 |
Enterprise Value | $47.21B | $3.49B |
Dividend Yield | 0.65% | — |
Signals from Pluang's Aura AI — not financial advice
STM's stock trades at $55.09, up 1.36% on the day, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.31, beating expectations, but faces profitability challenges with a net margin of 3.56%. Recent news highlights strong AI data center growth potential, targeting over $2 billion in revenues by 2027. Cash flow improved in 2025 with net cash flow of $555 million.
The outlook is mixed; analyst consensus is bullish with a $74.63 price target, but high P/E of 107.92 indicates premium valuation. Key opportunities include AI and auto demand, while risks involve margin pressure and competitive threats. Execution on growth targets is critical for upside.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →